The following is a list of top 10 US patents which are set to lose money in 2017 and beyond due to the expiry of patent protection and the increase in competition posed by generic versions of the drugs.  Exactly when a drug will lose market exclusivity isn’t clear because of add-on patents and legal settlements but history has shown that when generics come to market the branded drugs can lose up to 90% of their sales.

1) Copaxone 40 mg, multiple sclerosis medication by Teva Pharmaceutical Industries.  This drug was worth $3.48 billion in 2015 US sales.  Generic alternative drugs are set to reduce sales to $1.3 billion in 2017.

2) Cialis, erectile dysfunction drug by Eli Lilly & Company.  This drug represented sales of $1.42 billion in 2015 and will continue to remain strong in 2017 but its sales are expected to slide to $55 million in 2022.

3) Viagra, erectile dysfunction drug by Pfizer Inc.  This drug represented $1.15 billion US sales in 2015 and is expected to decline to $188 million by 2022.

4) Velcade, multiple myeloma medication by Takeda Pharmaceutical Company Ltd accounted for over $1 billion US sales in 2015. Following loss of patent protection it is set to loss about $1 billion in sales by 2022.

5) Sustiva, HIV medication by Bristol-Myers represented $901 million US sales in 2015.

6) Sandostatin LAR by Novartis International AG used to treat acromegaly and diarrhea associated with certain types of tumors.  The drug was worth $853 million in 2015 sales. Expeteced the bulk of its sales through 2022 despite the loss of patent protection as a “complex generic” the bar for copycat entry is high.

7) Norditropin SimpleXx growth hormone delivered in a proprietary pen device by Novo Nordisk.

8) Viread hepatitis B/HIV antiviral by Gilead Sciences Ltd.

9) Pristiq antidepressant drug by Pfizer Inc.

10) Strattera for the treatment of attention deficit hyperactivity disorder by Eli Lilly & Company accounted for $535 million US sales in 2015 which is expected to drop to $13 million by 2022.